for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sun Pharmaceutical Industries Limited

SUN.BO

Latest Trade

394.60INR

Change

8.30(+2.15%)

Volume

194,794

Today's Range

386.30

 - 

399.00

52 Week Range

350.40

 - 

616.50

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
386.30
Open
386.30
Volume
194,794
3M AVG Volume
145.94
Today's High
399.00
Today's Low
386.30
52 Week High
616.50
52 Week Low
350.40
Shares Out (MIL)
2,399.33
Market Cap (MIL)
926,863.10
Forward P/E
19.94
Dividend (Yield %)
0.71

Next Event

Q2 2020 Sun Pharmaceutical Industries Ltd Earnings Release

Latest Developments

More

India's Sun Pharma Raises Stake In PJSC Biosintez To 100%

Sun Pharmaceutical Industries Enters Licensing Agreement With China Medical System Holdings

Sun Pharmaceutical Industries Partners CSIR-IICT

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.

Industry

Biotechnology & Drugs

Contact Info

Acme Plaza

Andheri Kurla Road, Andheri East

+91.22.43244324

http://www.sunpharma.com/

Executive Leadership

Israel Makov

Non-Executive Chairman of the Board

C. S. Muralidharan

Chief Financial Officer

Sunil R. Ajmera

Compliance Officer, Company Secretary

Dilip Shantilal Shanghvi

Managing Director, Executive Director

Sailesh T. Desai

Whole-time Director

Key Stats

2.49 mean rating - 37 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

302.6K

2018

264.9K

2019

290.7K

2020(E)

329.2K
EPS (INR)

2017

29.000

2018

12.960

2019

16.060

2020(E)

19.352
Price To Earnings (TTM)
30.92
Price To Sales (TTM)
3.07
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
17.37
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Indian shares pare early gains; automakers weigh

* Nifty PSU bank index ends down 0.83%; SBI among top decliners

UPDATE 1-India's Sun Pharma Q3 profit jumps four-fold on strong U.S. show

India's largest drugmaker by market value Sun Pharmaceutical Industries Ltd posted a nearly four-fold jump in quarterly profit on Tuesday, breezing past estimates on strong sales in the U.S. market.

India's Sun Pharma Q3 profit rises nearly four-fold, beats estimate

Sun Pharmaceutical Industries Ltd , India's largest drugmaker by market value, posted a nearly four-fold jump in quarterly profit on Tuesday, beating estimates.

UPDATE 2-India's Sun Pharma takes steps to ease governance concerns; shares rally

* Shares jump over 6 pct (Adds analyst comments, updates share move)

India's Sun Pharma to make unit distributor for local formulations biz

Indian drugmaker Sun Pharmaceutical Industries Ltd said https://www.nseindia.com/corporate/SUNPHARMA456_22012019083723_IntimationSE20190122_001.pdf on Tuesday it will make its unit the new distributor for its domestic formulations business, replacing Aditya Medisales.

India's Sun Pharma tumbles on reports of fresh whistleblower complaint

Shares of Sun Pharmaceutical Industries Ltd <SUN.NS> plunged 13 percent on Friday to near six-year lows, hit by reports that a whistleblower filed a complaint to regulators over transactions involving the top Indian drugmaker and its co-promotor.

India's Sun Pharma asks regulator to examine media report

Sun Pharmaceutical Industries Ltd <SUN.NS> on Friday asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower that led to a sell-off in the company's shares.

India's Sun Pharma asks regulator to examine media report

Sun Pharmaceutical Industries Ltd on Friday asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower that led to a sell-off in the company's shares.

India's Sun Pharma tumbles on report of fresh allegations by whistleblower

Shares of India's Sun Pharmaceutical Industries Ltd slumped over 13 percent on Friday to near six-year low, after a media report of a complaint by a whistleblower raised fresh concerns on the drugmaker's corporate governance.

Indian shares at 1-week closing low; cenbank keeps rates on hold

Indian shares hit a one-week closing low on Wednesday after the country's central bank left interest rates unchanged, while resurgent trade worries dented global sentiment.

India's Sun Pharma tumbles after report of probe

Shares of India's Sun Pharmaceutical Industries sank more than 10 percent on Monday after a report of a regulatory probe against the country's biggest drug manufacturer by market value.

UPDATE 1-Indian drugmaker Sun Pharma swings to surprise quarterly loss

Sun Pharmaceutical Industries was sent to an unexpected second-quarter loss by a one-off charge for an antitrust litigation settlement.

India's Sun Pharma posts surprise quarterly loss on one-time charge

Sun Pharmaceutical Industries Ltd , India's largest drugmaker by market capitalisation, posted a surprise quarterly loss on Tuesday, hurt by a one-time charge due to a legal settlement.

UPDATE 1-India's Sun Pharma Q1 profit beats estimates as U.S. sales climb

* Stock top gainer on NSE index (Adds details on U.S. and India sales, share movement)

India's Sun Pharma quarterly profit beats estimates

India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a first-quarter profit on Tuesday, beating street estimates.

India's Sun Pharma says U.S. FDA clears Halol plant

India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) cleared its Halol drug plant, which had been under supply restrictions due to quality control failures.

Indian shares recover from early losses to end flat

* NSE index ended 0.01 pct down, BSE index closed 0.05 pct lower

Indian shares end higher; banks, oil firms gain

Indian shares ended higher for a third session on Monday, as lower crude prices and a firmer rupee lifted sentiment, with financial and oil stocks accounting for much of the gains.

Indian shares gain as crude oil slips; Sun Pharma top gainer

Indian equities gained for a third straight session on Monday as a sharp drop in crude prices and a recovery in the rupee boosted sentiment, while shares of Sun Pharmaceutical Industries saw their best day in over three years on strong fourth-quarter results.

UPDATE 2-India's Sun Pharma warns U.S. pricing pressure to hit 2019 profit

* Plans to reduce "unviable" generics research (Adds managing director comments from conference call)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up